Alpha-Synuclein Inhibitors for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease primarily focus on symptom relief and do not effectively modify the underlying disease progression. There is a need for therapies that can inhibit α-synuclein aggregation and cytotoxicity, as existing inhibitors like Posiphen lack specificity and potency.
Innovation Solution
Development of compounds that can block the 5′ untranslated region (5′UTR) of α-synuclein mRNA, preventing the formation of Lewy bodies in the mid-brain and cortex, thereby treating α-synuclein associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current symptom-relief therapies are used for Parkinson's disease, then patient quality of life is improved, but the underlying disease progression is not modified
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (α-synuclein aggregation) that drives disease progression, separating the treatment of underlying pathology from symptomatic management. By designing compounds that specifically bind to and inhibit α-synuclein aggregation, the invention addresses the root cause rather than just symptoms.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate between the α-synuclein protein and its pathological aggregation. These compounds act as molecular mediators that bind to α-synuclein and prevent its aggregation into toxic forms, thereby modifying disease progression while allowing symptomatic therapies to continue.
2Reliability
If Posiphen is used as an α-synuclein inhibitor, then some inhibition effect is achieved, but specificity and potency are insufficient to prevent Lewy body formation
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (such as β-turn mimetics and amphipathic structures) that are optimized to interact with specific regions of the α-synuclein protein. This localized molecular design enhances both specificity for α-synuclein and potency in preventing aggregation, overcoming the limitations of Posiphen.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds (such as hydrophobicity, charge distribution, and structural rigidity) to optimize their interaction with α-synuclein. This allows for fine-tuning of both specificity and potency, achieving superior performance compared to Posiphen.
Data Source
AI summary
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.